ANN ARBOR – Tangent Medical Technologies, a development stage medical device company focused on next generation intravenous access systems, has hired former Accuri Cytometers CEO Jeffrey S. Williams as its Chief Executive Officer. Williams also will serve as Chairman of the board of directors.
While at Accuri, he oversaw revenue growth of 65 percent year-over-year, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, Williams had been President & CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, he led the growth and venture financing of the company, ultimately resulting in its sale for $275 million in November 2009. Previously, Mr. Williams was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997.
He received a BS in Biology from Alma College and an MBA from The University of Michigan. In addition to Tangent, Williams is a member of several boards, including Life Magnetics, where he serves as Executive Chairman.
Williams succeeds Hank Brown, founding investor and interim CEO since Tangent’s inception in July 2009.
“I’m convinced that with Jeff’s dedicated leadership and drive Tangent will be in a great position to execute its business plan to advance blood containment and catheter securement technology in the peripheral intravenous catheter market,” said Brown who will continue to serve on the company?s board. “It’s fantastic that the Tangent team was able to attract such a significant and accomplished CEO. As an added bonus, he is local and well known in the community.”
Tangent Medical, a development stage medical device company, is based on technology exclusively licensed from the University of Michigan’s Medical Innovation Center. The company’s mission is to improve infusion therapy safety for patients and healthcare workers with its proprietary, intravenous (IV) catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The company expects to begin generating commercial revenues from its lead product, the NovaCath peripheral IV system with integrated stabilization and blood containment, in 2012.
a>>
